newsfilter
← Latest News
GlobeNewswire·

Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2

Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targeting the novel tumor associated antigen 5T4 advances toward